US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Latest News about ASH21

Recent news which mentions ASH21

BeyondSpring's New Plinabulin Data Shows Fast Onset In Preventing Chemo-Induced Neutropenia
Tickers BYSI
Tags Briefs Health Care why it's moving
From Benzinga
Global Blood Raises $300M Via Convertible Debt Offering
Tickers GBT
Tags Offerings Biotech Movers
From Benzinga
Roche's Polivy Combo Boosts Survival In Early-Stage Lymphoma Patients
Tickers RHHBF RHHBY RHHVF
Tags ASH21 Trading Ideas RHHVF
From Benzinga
Sanofi Reveals Late-Stage Data For Fitusiran In Hemophilia Patients
Tickers SNY
Tags Hemophilia A News Phase 3 Trial
From Benzinga
Agios Presents Mitapivat Long-Term Data On Hemoglobin Response, Transfusion Burden
Tickers AGIO
Tags AGIO Benzinga Biotech
From Benzinga
Precigen Reveals Early Data From CAR-T Candidate In Blood Cancer Patients
Tickers PGEN
Tags Benzinga acute myeloid leukemia Biotech
From Benzinga
Atara Bio Unveils Pivotal Data On T Cell Therapy Tabelecleucel In Transplant Patients
Tickers ATRA
Tags Small Cap Health Care Briefs
From Benzinga
Aptose Shares Fall After HM43239 Data Featured At ASH Annual Meeting, Luxeptinib, APTO-253 Update
Tickers APTO
Tags Phase 2 Trial Phase 1 Trial Health Care
From Benzinga
Fate Therapeutics Showcases Interim Data From FT596 Cell Program In Lymphoma
Tickers FATE
Tags Trading Ideas FATE ASH21
From Benzinga
Gilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients
Tickers GILD
Tags General Benzinga Biotech
From Benzinga
Syndax Pharma Posts Additional Data On Clinical Activity, Responses From Early-Stage Leukemia Trial
Tickers SNDX
Tags Biotech Benzinga General
From Benzinga
ALX Oncology's Evorpacept Data Fails To Impress At ASH Presentation
Tickers ALXO
Tags Health Care Briefs why it's moving
From Benzinga
Why Did X4 Pharmaceuticals Shares Crater To 52-Week Low?
Tickers XFOR
Tags Movers Biotech Benzinga
From Benzinga
Viracta Therapeutics Posts Data From Lymphoma Trial At ASH Presentation
Tickers VIRX
Tags Phase 1 Trial Phase 2 Trial Briefs
From Benzinga
Comparing Data: Sanofi Vs. Johnson & Johnson Multiple Myeloma Therapies In Newly Diagnosed Patients
Tickers BMY JNJ SNY TAK
Tags multiple myeloma Market News News
From Benzinga
Harpoon Shares Jump After Early Data From BCMA-Targeting Myeloma Candidate At ASH Meet
Tickers HARP
Tags Briefs Health Care Phase 2 Trial
From Benzinga
JNJ's Janssen Posts Two Years Survival Data On BCMA Cell Therapy In Multiple Myeloma
Tickers JNJ LEGN
Tags Benzinga Biotech General
From Benzinga
Jazz Posts New Data for ALL/LBL Treatment At ASH 2021 Annual Meeting
Tickers JAZZ
Tags News Phase 3 Trial Market News
From Benzinga
Roche Uncorks Favorable Responses From Mosunetuzumab In Follicular Lymphoma Settings
Tickers RHHBF RHHBY RHHVF
Tags Benzinga Biotech RHHBF
From Benzinga
New Data At ASH21 Show Bluebird's Thalassemia Gene Therapy Potentially Curative One-Time Treatment
Tickers BLUE
Tags Long Ideas News Market News
From Benzinga
Bluebird Bio Posts Updated Data From Sickle Cell Gene Therapy Program
Tickers BLUE
Tags Health Care Briefs Phase 1 Trial
From Benzinga
Gilead's Kite Unveils More Data On Yescarta In Second-Line Lymphoma Patients
Tickers GILD
Tags ASH21 lymphoma Phase 3 Trial
From Benzinga